Quantcast

China Medical Technologies Receives SFDA Approval for its Fully-Automated ECLIA Analyzer (AUTOMAGLIA 90) and SFDA Approval for its Down Syndrome Screening Kit

April 29, 2010

BEIJING, April 29 /PRNewswire-Asia-FirstCall/ — China Medical
Technologies, Inc. (the “Company”) (Nasdaq: CMED), a leading China-based
advanced in-vitro diagnostic (“IVD”) company, today announced that it received
approval for its AUTOMAGLIA 90 fully-automated ECLIA analyzer (“AUTOMAGLIA 90
Analyzer”) as well as Down Syndrome screening kit (“Down Syndrome Screening”)
from the State Food and Drug Administration of China (the “SFDA”).

AUTOMAGLIA 90 Analyzer is a fully-automated analyzer for immunoassay
analysis in various types of diseases and disorders. Major clinical diagnostic
applications include thyroid disorders, fertility and infertility disorders,
diabetes, infectious diseases and tumor markers. The Company expects
AUTOMAGLIA 90 Analyzer to enter a new customer segment of its ECLIA business
by targeting large hospitals in China which have the highest patient volume
and consumable usage. The Company will leverage its own direct sales force to
cross sell AUTOMAGLIA 90 Analyzer to existing FISH customers which comprise
over 400 large hospitals in China.

Down Syndrome Screening is used for prenatal screening tests for trisomy
21, a chromosomal disorder caused by the presence of all or part of an extra
21st chromosome. The Company plans to bundle Down Syndrome Screening with its
Prenatal FISH Probe, a molecular diagnostic test for the detection of various
prenatal disorders with a view of serving a huge group of pregnant women in
China at an estimated size of over 16 million each year.

“We are pleased to receive SFDA approval for both AUTOMAGLIA 90 Analyzer
and Down Syndrome Screening,” said Mr. Xiaodong Wu, Chairman and Chief
Executive Officer of the Company. “We expect the approved products to broaden
our customers and increase usage of our consumables. We look forward to
receive SFDA approval for our HPV DNA Chip which is also expected to broaden
our customers and increase our consumable usage.”

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVD
company using molecular diagnostic technologies including Fluorescent in situ
Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology
as well as Enhanced Chemiluminescence Immunoassay (ECLIA) technology, an
immunodiagnostic technology to develop, manufacture and distribute diagnostic
products for the detection of various cancers, diseases and disorders. The
Company generates all revenues in China by selling diagnostic consumables
including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals
which are recurring users of the consumables for their patients. The Company
sells FISH probes and SPR chips to large hospitals through its direct sales
force and ECLIA reagent kits to small and mid-size hospitals through
distributors. For more information, please visit http://www.chinameditech.com .

Safe Harbor Statement

This press release contains forward-looking statements. These statements
constitute “forward-looking” statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These forward-looking
statements can be identified by terminology such as “will,” “expects,”
“anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and
similar statements. Such statements involve certain risks and uncertainties
that could cause actual results to differ materially from those in the
forward-looking statements. Further information regarding these and other
risks is included in the Company’s filings with the U.S. Securities and
Exchange Commission, including its annual report on Form 20-F. The Company
does not undertake any obligation to update any forward-looking statement as a
result of new information, future events or otherwise, except as required
under applicable law.

    For more information, please contact:

     Winnie Yam
     Tel:   +852-2511-9808
     Email: IR@chinameditech.com

SOURCE China Medical Technologies, Inc.


Source: newswire



comments powered by Disqus